{"brief_title": "A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies", "brief_summary": "The purpose of this study is to determine the side effects and antitumor response of patients with lymphoid malignancies to Deoxycoformycin (DCF)/Pentostatin.", "detailed_description": "Deoxycoformycin(DCF)/Pentostatin is a T-cell cytotoxic drug with previously reported responses in lymphoid malignancies but larger studies are needed.", "condition": ["Peripheral T-cell Lymphoma", "Cutaneous T-cell Lymphoma", "Chronic Lymphocytic Leukemia"], "intervention_type": ["Drug"], "intervention_name": ["Deoxycoformycin (DCF)"], "description": ["Patients received Deoxycoformycin (DCF)/Pentostatin administered by intravenous bolus daily over a consecutive 3-day period. This course was repeated at 3-week intervals."], "arm_group_label": ["Deoxycoformycin (DCF)/Pentostatin"], "other_name": ["Nipent", "Pentostatin"], "criteria": "Inclusion Criteria: - Histologic proof of lymphoid malignancy with an expected complete response rate of less than 20 percent OR have failed at least one prior therapy. - No chemotherapy within 3 weeks of entry into study and must have recovered from acute toxic effects of prior therapy. - Life expectancy of at least 12 weeks. - Performance status equal to or less than Zubrod 2. - Signed informed consent. - Patients with measurable disease. - Age at least 16 years. - Adequate bone marrow function (unless involvement of bone marrow by lymphoma) defined as AGC greater than 1500 and platelet count greater than 100,000. - Adequate hepatic function with a bilirubin less than or equal to 1.5 mg % and SGPT less than or equal to 4 times the upper limits of normal. - Adequate renal function defined as serum creatine less than or equal to 1.5 mg %. Exclusion Criteria: - No serious intercurrent illness. - Adequate contraception (if applicable). - NO patients with significant cardiac disease, i.e. New York Heart Association (NYHA) class III or IV. - NO experimental clinical trial within 3 weeks of study entry. - NO patients with active CNS disease. - Full recovery from any prior surgical treatment. - NO active active infections.", "gender": "All", "minimum_age": "16 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "T-cells", "mesh_term": ["Lymphoma", "Leukemia, Lymphoid", "Leukemia, Lymphocytic, Chronic, B-Cell", "Lymphoma, T-Cell", "Lymphoma, T-Cell, Peripheral", "Lymphoma, T-Cell, Cutaneous", "Pentostatin"], "id": "NCT00038025"}